SynthesisJournal of cosmetic dermatology2025
The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta-Analysis Study.
Synthesis in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Evidence Synthesis Gone Awry: The Perils of Aggregating Ineffective or Unsafe Doses in Alopecia Areata Reviews.Cureus · 2026Article
- Oral Ivarmacitinib for Stable Vitiligo: Preliminary Observations from a Three-Patient Case Series.Clinical, cosmetic and investigational dermatology · 2026Article
- JAK Inhibitors for Alopecia Areata: Approved Therapies, Efficacy, and Unanswered Questions.Drug design, development and therapy · 2026Review
- Development Trends of Janus Kinase Inhibitors (JAKi) Over Three Decades: From Common to Rare Diseases.Drug design, development and therapy · 2026Review
- Real World Evidence in Alopecia Areata: Current Management, Emerging Therapies and Future Challenges - A Narrative Review.Journal of inflammation research · 2026Review
- Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundScant evidence exists for the relative efficacy of therapies for alopecia areata (AA)-including those approved by the Food and Drug Administration, namely, baricitinib, deuruxolitinib, and ritlecitinib.
aimsWe determined the relative efficacy and safety of monotherapy with janus kinase inhibitors (JAKIs), apremilast, and dupilumab.
methodsFollowing a systematic review, we conducted Bayesian network meta-analysis (NMAs) that produced Surface Under the Cumulative RAnking (SUCRA) values and point estimates for pairwise relative effects; we also performed sensitivity analyses.
resultsIn total, regimens with eight various JAKIs were compared, namely, ruxolitinib, ATI-501, baricitinib, brepocitinib, deuruxolitinib, ivarmacitinib, ritlecitinib, and tofacitinib. Our analyses ranked "deuruxolitinib 12 mg twice daily for 24 weeks," the most efficacious insofar as "proportion of participants achieving SALT ≤ 20 at 24 weeks" (SALT
conclusionsWe produced high-quality evidence on the comparative effectiveness of monotherapies for AA with various regimens of 8 JAKIs, including the FDA-approved ones. Our findings can improve clinicians' decision-making and update guidelines for medical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.